

BHAGERIA & JAJODIA PHARMACEUTICALS PRIVATE LIMITED
AUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED MARCH 31, 2026
(Rs. in Lakhs)

PARTICULARS	Quarter Ended			Year Ended	
	(Audited)	(Unaudited)	(Audited)	(Audited)	(Audited)
	31-03-2026	31-12-2025	31-03-2025	31-03-2026	31-03-2025
1 Revenue from operations (Net of GST)	33.45	15.91	201.10	225.41	618.57
2 Other income	2.11	1.99	2.17	8.48	7.95
3 Total Income (1+2)	35.56	17.90	203.27	233.88	626.52
4 Expenses					
Cost of materials consumed	-	-	-	-	-
Purchase of Stock-in-Trade	99.76	54.78	304.64	419.56	851.69
Changes in inventories of finished goods, work-in-progress and Stock-in-Trade	-	-	-	-	-
Employee benefit expense	0.76	1.51	-	2.83	-
Finance costs	31.88	31.28	29.62	119.37	115.93
Depreciation and amortization expense	-	-	-	-	-
Other expenses	12.97	1.37	1.54	16.57	8.65
Total expenses	145.37	88.94	335.80	558.33	976.27
5 Profit before tax (3-4)	(109.81)	(71.04)	(132.53)	(324.45)	(349.75)
6 Tax expense:	-	-	-	-	-
Current tax	-	-	-	-	-
Deferred tax	-	-	-	-	-
(Excess) / Short Provision for tax	-	-	-	-	-
7 Profit for the period (5-6)	(109.81)	(71.04)	(132.53)	(324.45)	(349.75)
8 Other comprehensive income					
Items that will not be reclassified to profit or loss					
i. Remeasurement of the defined benefit plans	-	-	-	-	-
ii. Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-	-
Total other comprehensive income for the period (net of tax)(i+ii)	-	-	-	-	-
9 Total Comprehensive Income for the period (7+8)	(109.81)	(71.04)	(132.53)	(324.45)	(349.75)
10 Paid up Capital					
Face value of share (Rs.)	10.00	10.00	10.00	10.00	10.00
11 Reserve excluding Revaluation Reserves as per balance sheet of previous accounting year	-	-	-	(436.49)	(112.04)
12 Earnings per equity share (EPS) :					
Basic EPS (Rs) (not annualised)	(21.96)	(14.21)	(26.51)	(64.89)	(69.95)
Diluted EPS (Rs) (not annualised)	(21.96)	(14.21)	(26.51)	(64.89)	(69.95)
Face value of share (Rs)	10.00	10.00	10.00	10.00	10.00